Infliximab Biosimilar Market Competitive Landscape and Outlook 2026 to 2035

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1060

Infliximab is a chimeric monoclonal antibody that specifically targets tumor necrosis factor-alpha (TNF-α) and is indicated for the management of various chronic inflammatory disorders, including ankylosing spondylitis, Crohn's disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Biosimilar formulations of infliximab have demonstrated comparable efficacy and safety profiles to the reference biologic, commonly marketed under the brand name Remicade. Production of infliximab involves the continuous perfusion of a recombinant cell line, with TNF-α serving as a pivotal proinflammatory cytokine implicated in the pathophysiology of these chronic conditions.

The infliximab biosimilar market is driven by several factors, including the rising prevalence of autoimmune disorders-particularly rheumatoid arthritis and plaque psoriasis-the expiration of patents on branded biologics, competitive pricing in European markets, and the rapid therapeutic response afforded by intravenous administration. Policy initiatives and reimbursement programs designed to contain healthcare expenditures have further accelerated the adoption of biosimilars. Additional growth contributors include the cost-effectiveness of infliximab biosimilars, the increasing incidence of chronic diseases such as autoimmune disorders and cancer, and the expanding elderly population globally.

Nevertheless, market expansion faces certain challenges, including limited physician acceptance, a relatively modest pricing advantage compared to small-molecule generics, and the persistence of patent protections in select regions. Safety concerns, including adverse effects such as histoplasmosis, bacterial sepsis, and tuberculosis, may also constrain broader market uptake.

Add our site to Google Preferred Sources for quality content: https://google.com/preferences/source?q=insightaceanalytic.com

Europe currently leads the global biosimilars market, followed by the Asia-Pacific and North American regions. Key growth drivers include the impending patent expirations of several biologic drugs, the introduction of new biosimilar products, and the entry of emerging companies seeking early market positioning. North America is expected to emerge as a significant contributor to the infliximab biosimilar market over the forecast period. Market expansion is largely supported by the rising prevalence of autoimmune and genetic disorders, including plaque psoriasis and rheumatoid arthritis.

Additional factors stimulating growth include the increasing geriatric population with limited access to effective diagnostics and therapies, enhancements in healthcare infrastructure, and opportunities in underpenetrated markets. Moreover, government initiatives promoting biosimilar production, coupled with heightened awareness and adoption of biosimilars among healthcare providers and patients, are projected to further propel the infliximab biosimilar market in this region.

Major market players operating in the Infliximab Biosimilar market include
Napp Pharmaceuticals Group Ltd, Alvogen, Merck &Co. Inc., Celltrion Inc., Janssen Biotech Inc., Pfizer Inc. (AC. Hospira), and Nippon Kayaku.

Recent collaborations and agreements in the market:
• In April 2021, Novartis AG (Sandoz) struck a deal with Bio-Thera Solutions (China) to commercialise BAT1706 (Bio-Thera Solutions' proposed bevacizumab biosimilar) in the United States, Canada, Europe, and other international markets.
• In November 2019, Biogen Inc, a multinational biotechnology company headquartered in Cambridge, Massachusetts, purchased Samsung Bioepis Co., Ltd. in order to obtain exclusive rights to market two new ophthalmology biosimilars, SB11 referencing Lucentis 1 and SB15 referencing Eylea 2, in major markets around the world, including the United States, Canada, Europe, Japan, and Australia. The deal allows Biogen to prolong the commercialization time for Samsung Bioepis' three anti-TNF biosimilars, BENEPALI (etanercept), FLIXABI (infliximab), and IMRALDI, in Europe (adalimumab). Samsung Bioepis is a biopharmaceutical company. It makes biosimilar medications and other related products.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1060

Market Segments
Global Infliximab Biosimilar Market, by Application, 2022-2030 (Value US$ Mn)
• Crohn's Disease
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis
• Ankylosing Spondylitis
• Plaque Psoriasis and others
Global Infliximab Biosimilar Market, by End User, 2022-2030 (Value US$ Mn)
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Other Direct Distribution Channels
Global Infliximab Biosimilar Market, by Mode, 2022-2030 (Value US$ Mn)
• Prescription-Based Testing Products
• Over-the-Counter (OTC) Testing Product
Global Infliximab Biosimilar Market, by End-Users, 2022-2030 (Value US$ Mn)
• Home Care/Self Testing
• Physician offices & Outpatient/Ambulatory Care Settings
• Hospitals
• Research Laboratories
Global Infliximab Biosimilar Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Infliximab Biosimilar Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Infliximab Biosimilar Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Infliximab Biosimilar Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Infliximab Biosimilar Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Infliximab Biosimilar Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global Infliximab Biosimilar market
 To receive an industry overview and future trends of the Infliximab Biosimilar market
 To analyze the Infliximab Biosimilar market drivers and challenges
 To get information on the Infliximab Biosimilar market value (US$Mn) forecast to 2030
 Significant investments, mergers & acquisitions in the Infliximab Biosimilar market industry

Read Overview Report- https://www.insightaceanalytic.com/report/global-infliximab-biosimilar-market-/1060

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.